TET2 and mature T-cell and NK-cell non-Hodgkin lymphoma: This evidence suggests that targeting aberrant DNA methylation in PTCL with TET2 mutation could offer an alternative to conventional chemotherapy regimens, though this hypothesis needs to be studied further.